BE2014C071I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C071I2
BE2014C071I2 BE2014C071C BE2014C071C BE2014C071I2 BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2 BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2
Authority
BE
Belgium
Application number
BE2014C071C
Other languages
French (fr)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C071(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BE2014C071I2 publication Critical patent/BE2014C071I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2014C071C 2004-06-11 2014-11-28 BE2014C071I2 (esLanguage)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004174770 2004-06-11
JP2004327111 2004-11-10
US63059604P 2004-11-23 2004-11-23
US11/150,792 US7378423B2 (en) 2004-06-11 2005-06-10 Pyrimidine compound and medical use thereof

Publications (1)

Publication Number Publication Date
BE2014C071I2 true BE2014C071I2 (esLanguage) 2024-10-08

Family

ID=35600249

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C071C BE2014C071I2 (esLanguage) 2004-06-11 2014-11-28

Country Status (2)

Country Link
US (8) US7378423B2 (esLanguage)
BE (1) BE2014C071I2 (esLanguage)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006090930A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の新規併用
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
WO2009049018A1 (en) * 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
JP2011511071A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 肺癌を治療するためのピコプラチンおよびアムルビシン
MX336723B (es) * 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
WO2010059658A1 (en) 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
US8647067B2 (en) * 2008-12-09 2014-02-11 General Electric Company Banked platform turbine blade
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
BRPI1013561A8 (pt) * 2009-03-26 2015-09-22 Mapi Pharma Ltd processo para a preparação de alogliptina
SG179144A1 (en) * 2009-09-23 2012-05-30 Glaxosmithkline Llc Combination
JP2013505939A (ja) * 2009-09-23 2013-02-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
EA201270475A1 (ru) 2009-09-28 2012-11-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация
RS65800B1 (sr) 2009-10-16 2024-08-30 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
AU2010322105B2 (en) * 2009-11-17 2014-05-08 Novartis Ag Combination
US8637246B2 (en) 2010-02-25 2014-01-28 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
ES2530755T3 (es) * 2010-05-21 2015-03-05 Glaxosmithkline Llc Terapia de combinación para el tratamiento del cáncer
JP5903433B2 (ja) 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
EP2640390A4 (en) * 2010-11-17 2014-08-06 Glaxosmithkline Ip No 2 Ltd METHODS OF TREATING CANCER
JP6063871B2 (ja) 2010-12-20 2017-01-18 ノバルティス アーゲー 組合せ
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CA2846454A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
TR201811976T4 (tr) * 2012-03-14 2018-09-21 Lupin Ltd Mek inhibitörleri olarak heterosiklil bileşikleri.
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CA2879252C (en) 2012-08-17 2017-10-10 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
MX2015005307A (es) * 2012-10-25 2015-07-17 Glaxosmithkline Llc Combinacion.
IL300664A (en) 2012-11-30 2023-04-01 Novartis Ag Innovative pharmaceutical composition
CA2897559A1 (en) 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combination
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AR096433A1 (es) 2013-05-28 2015-12-30 Glaxosmithkline Intellectual Property (No 2) Ltd Método de tratamiento del cáncer y uso
CA2909052A1 (en) 2013-06-03 2014-12-11 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
AU2014362995A1 (en) 2013-12-12 2016-05-26 Novartis Ag Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
JP2018526377A (ja) 2015-08-28 2018-09-13 ノバルティス アーゲー がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
US10861357B2 (en) * 2015-11-13 2020-12-08 Nike, Inc. Athletic bib
RU2605400C1 (ru) * 2015-11-13 2016-12-20 ЗАО "Р-Фарм" ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
KR101796684B1 (ko) * 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3873474A4 (en) * 2018-10-30 2022-07-13 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS
MY202884A (en) 2018-11-30 2024-05-28 Univ North Carolina Chapel Hill Compounds useful in hiv therapy
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
WO2020161654A1 (en) * 2019-02-06 2020-08-13 Aurobindo Pharma Limited A process for the preparation of trametinib acetic acid solvate
MX2022000050A (es) 2019-07-02 2022-05-24 Nuvation Bio Inc Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
MX2022001328A (es) * 2019-07-30 2022-05-20 Edvince Ab Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers
US12268692B2 (en) 2020-04-10 2025-04-08 Postsurgical Therapeutics, Inc. Combinatorial targeted therapy methods
WO2021263188A1 (en) * 2020-06-25 2021-12-30 Icahn School Of Medicine At Mount Sinai Live cell engagement assay
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
CN114853754B (zh) * 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
JPWO2024209717A1 (esLanguage) 2023-04-06 2024-10-10

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3139432A (en) 1963-06-24 1964-06-30 Mead Johnson & Co Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones
DE4035479A1 (de) 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
EP1140046A1 (en) 1998-12-15 2001-10-10 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
WO2000035436A2 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
HUP0104933A3 (en) 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
TR200200205T2 (tr) 1999-07-16 2002-06-21 Warner-Lambert Company MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
KR100773621B1 (ko) 2000-07-19 2007-11-05 워너-램버트 캄파니 엘엘씨 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르
AU2001271067A1 (en) 2000-07-19 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound
WO2002087620A1 (en) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
PL220952B1 (pl) 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof

Also Published As

Publication number Publication date
US20170029418A1 (en) 2017-02-02
US20220380362A1 (en) 2022-12-01
US7378423B2 (en) 2008-05-27
US20150183812A1 (en) 2015-07-02
US20060014768A1 (en) 2006-01-19
US20200109139A1 (en) 2020-04-09
US20180273531A1 (en) 2018-09-27
US8835443B2 (en) 2014-09-16
US20080312228A1 (en) 2008-12-18
US20100240613A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
BE2014C071I2 (esLanguage)
FR14C0074I1 (esLanguage)
JP2004332738A5 (esLanguage)
JP2005152651A5 (esLanguage)
JP2005199058A5 (esLanguage)
JP2005273771A5 (esLanguage)
JP2004360065A5 (esLanguage)
JP2005086802A5 (esLanguage)
JP2004356097A5 (esLanguage)
JP2005148717A5 (esLanguage)
JP2004340143A5 (esLanguage)
JP2005048581A5 (esLanguage)
JP2005057989A5 (esLanguage)
JP2004348722A5 (esLanguage)
TWI367481B (esLanguage)
JP2005012996A5 (esLanguage)
JP2005226415A5 (esLanguage)
JP2005245479A5 (esLanguage)
JP2005206070A5 (esLanguage)
JP2005227860A5 (esLanguage)
GB2416843A8 (esLanguage)
JP2005229505A5 (esLanguage)
DE602005017471D1 (esLanguage)
JP2005172794A5 (esLanguage)
JP2005141895A5 (esLanguage)